An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Nilotinib (Primary)
- Indications Cancer; Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 May 2018 Planned End Date changed from 18 Dec 2023 to 28 Apr 2023.
- 10 May 2018 Planned primary completion date changed from 18 Dec 2023 to 28 Apr 2023.
- 03 Oct 2017 Status changed from active, no longer recruiting to recruiting.